Vimarsana
Biggest News Aggregation in the World

Cellular Therapist News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cellular Therapist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cellular Therapist Today - Breaking & Trending Today

Anti-Tobacco Day: 5 Ways How Second-Hand Smoking Can Be Dangerous - Vimarsana News

Anti-Tobacco Day: 5 Ways How Second-Hand Smoking Can Be Dangerous

Second hand smoking or passive smoking is dangerous in itself. Expert reveals how it may take a toll on your body. - Anti-Tobacco Day: 5 Ways How Second-Hand Smoking Can Be Dangerous - Expert Speaks!

Source: india.com
One-Time Cell Therapy Amtagvi Gets Accelerated Approval for Advanced Melanoma - Vimarsana News

One-Time Cell Therapy Amtagvi Gets Accelerated Approval for Advanced Melanoma

Amtagvi is a tumor-derived autologous T cell immunotherapy designed to deploy patient-specific T cells called TIL cells to locate and attack cancer cells.

One-Time Cell Therapy Amtagvi Gets Accelerated Approval for Advanced Melanoma - Vimarsana News

One-Time Cell Therapy Amtagvi Gets Accelerated Approval for Advanced Melanoma

Amtagvi is a tumor-derived autologous T cell immunotherapy designed to deploy patient-specific T cells called TIL cells to locate and attack cancer cells.

Source: empr.com
Novel immunotherapy approved for melanoma - Vimarsana News

Novel immunotherapy approved for melanoma

Amtagvi is the first tumour-derived autologous T cell immunotherapy therapy to be approved by the US Food and Drug Administration for certain adults with unresectable or metastatic...

Iovance's AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma -February 16, 2024 at 03:20 pm EST - Vimarsana News

Iovance's AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma -February 16, 2024 at 03:20 pm EST

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune...